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Resumo  
 
Introdução 
A doença inflamatória intestinal está associada a risco acrescido de cancro 
colorretal. Embora a carcinogénese associada a esta doença ainda seja mal 
conhecida, sabe-se que os mecanismos não são idênticos à sequência de adenoma-
carcinoma do cancro esporádico e que as alterações genómicas são semelhantes, 
mas diferem na frequência e na ordem de eventos carcinogénicos. De forma a 
poder intervir precocemente, através de estratégias preventivas do 
desenvolvimento tumoral, é essencial a compreensão dos perfis genéticos e 
moleculares por detrás da carcinogénese, para permitir diagnóstico precoce, 
prevenção e tratamento mais eficazes, como também prever a resposta terapêutica 
e identificar biomarcadores prognósticos. Até agora, poucas moléculas estão 
propostas como possíveis biomarcadores, mas é provável que a Glicomedicina 
traga respostas nesta área. 
 
Objetivos 
Revisão científica relativa à associação entre doença inflamatória intestinal e 
cancro colorretal, com destaque para as alterações a nível histológico e molecular 
que diferenciam a carcinogénese nestes casos da dos cancros esporádicos, bem 
como para os novos biomarcadores, sublinhando a importância que os glicanos 
têm vindo a ganhar nesta área. 
 
Metodologia 
Revisão de publicações científicas acedidas, maioritariamente, através da base 
de dados informatizada PubMed. De entre os artigos originais e de revisão 
publicados entre 2008 e 2019, em inglês, selecionei aqueles considerados de 
maior relevância, atualidade e rigor científico. As bibliografias destes artigos foram 
também analisadas para possivelmente identificar outras publicações a incluir na 
revisão.  
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Conclusões 
A abordagem dos doentes com doença inflamatória intestinal tem ainda 
questões por resolver, incluindo necessidade de melhor tratamento e prevenção de 
complicações, nomeadamente o cancro colorretal. Em relação à prevenção, existem 
dados contraditórios sobre o efeito quimioprofilático dos anti-TNF, 5-ASAs e 
tiopurinas e, considerando que aumentam o risco de infeções e de alguns cancros, 
é importante avaliar a relação risco/benefício do seu uso crónico. Novas terapias 
estão a ser aprovadas, mas sua eficácia e segurança a longo prazo ainda não são 
bem conhecidas. Colonoscopias de vigilância também são altamente 
recomendadas, mas há dúvidas quanto à melhor técnica e altura em que devem ser 
realizadas, uma vez que alguns cancros se desenvolveram antes do início da 
vigilância, o que pode explicar por que não há redução da mortalidade associada. 
Foram feitas algumas descobertas sobre a patogénese do cancro colorretal 
associado à doença inflamatória intestinal, que destacam o papel da resposta 
inflamatória e imunológica crónica como potenciadora das alterações genéticas 
carcinogénicas e que apoiam a possibilidade da contribuição do microbioma 
intestinal, visto que casos de cancro têm mais disbiose do que indivíduos 
saudáveis. 
Em relação aos novos biomarcadores, a Glicomedicina parece ser muito 
promissora, tendo já revelado que níveis de N-glicanos ramificados, anticorpos 
anti-glicano e glicosilação das imunoglobulinas G podem constituir biomarcadores 
prognósticos precoces, e que a N-acetilglucosamina pode ser uma estratégia 
imunomoduladora específica e não tóxica para tratamento e quimioprofilaxia do 
cancro colorretal. 
 
Palavras-chave 
Biomarcadores; Cancro associado a Doença Inflamatória Intestinal; Cancro 
colorretal; Carcinogénese; Doença Inflamatória Intestinal; Glicanos.  
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Abstract 
 
Introduction 
Inflammatory bowel disease is associated with higher risk of colorectal cancer. 
Although colitis-associated cancer’ pathogenesis remains unclear, it is known that 
the carcinogenic mechanisms differ from the adenoma-carcinoma sequence of 
sporadic cancer and that genomic alterations are similar but differ in frequency and 
in order of carcinogenic events. More than trying to prevent cancer, by improving 
disease treatment and surveillance, it is important to better understand the genetic 
and molecular profiles behind these cases’ carcinogenesis, allowing earlier 
diagnosis, more effective prevention and treatment strategies, predicting therapy 
response and identifying prognostic biomarkers. So far, there are very few 
molecules proposed to be possible biomarkers, but it is likely that Glycomedicine 
research will bring new answers to this question. 
 
Objectives 
Scientific review on the association between colorectal cancer and inflammatory 
bowel disease, highlighting the histological and molecular changes that 
differentiate these cases carcinogenesis from that of sporadic cancers, as well as 
the new biomarkers, underlining the importance that glycans have been gaining in 
this matter.  
 
Methods 
Review of scientific publications accessed, mainly, through the computerized 
PubMed database. Among the original and review articles published between 2008 
and 2019, in English, I selected those considered of greater relevance and scientific 
rigor. Those articles references were also analyzed to possibly identify other 
publications to be included in the review. 
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Conclusions 
Inflammatory bowel disease’ management still has unresolved issues, including 
need for better treatment and prevention of complications, namely colorectal 
cancer. Regarding prevention, there is conflicting data about the 
chemoprophylactic effect of anti-TNF, 5-ASAs and thiopurines and, considering 
they raise the risk of infections and of some cancers, it is important to assess the 
benefit/risk ratio of their long-term use. New therapies are being approved, but 
their long-term efficacy and safety are not well known yet. Colonic surveillance is 
highly recommended, but doubts remain regarding the best technique and timing 
in which colonoscopies should be performed, since some cancers developed before 
surveillance started, which may explain why there is no mortality reduction 
associated with it. 
There are some new answers about the pathogenesis of colitis-associated 
colorectal cancer, which highlight the role of the chronic inflammatory and immune 
response as a potentiator of the carcinogenic genetic alterations and that support 
the possibility of intestinal microbiome contribution in carcinogenesis, since cancer 
cases have more dysbiosis than healthy individuals. 
Regarding new disease biomarkers, Glycomedicine seems very promising in this 
matter and already revealed that levels of branched N-glycans, anti-glycan 
antibodies and immunoglobulin G glycosylation can constitute early prognostic 
biomarkers, and that N-acetylglucosamine can be an inexpensive and nontoxic 
targeted-specific immunomodulatory strategy for treatment and 
chemoprophylaxis.  
 
Key Words 
Biomarkers; Carcinogenesis; Colitis-Associated Cancer; Colorectal Cancer; 
Glycans; Inflammatory Bowel Disease.  
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Introduction 
Inflammatory bowel disease (IBD) – including Chron’s disease (CD) and Ulcerative 
Colitis (UC) – constitutes a global public health challenge, associated with high 
morbidity, mortality and health-care costs
5,6
. Overall, patients with IBD have higher 
risk of colorectal cancer (CRC) than healthy individuals, which is one of the most 
feared complications of the disease
7–10
.  
Although the pathogenesis of colitis-associated colorectal cancer (CAC) remains 
unclear, some risk factors have been identified, and it seems that the inflammatory 
burden is the most important
11,12
. Therefore, a successful anti-inflammatory 
treatment, promoting high mucosal healing rates is essential in cancer 
prevention
12
. However, as a life-long illness, IBD has periods of relapse and 
remission and some patients do not respond to treatment or lose the initial 
response, so the inflammatory burden differs between individuals with the same 
disease duration
11,13–21
. Current therapies are based on anti-inflammatory drugs, 
immunomodulators and biologic agents that suppress the immune system but have 
undesired risks when used chronically
22–24
. Besides treatment, an important concern 
on this matter is cancer screening and surveillance, since the high mortality is 
partially due to diagnosis at late stages
7
. Colonic surveillance of IBD patients is 
highly recommended, in order to detect potentially resectable dysplastic lesions or 
potentially surgically curable early stage CAC, reducing its morbidity and 
mortality
9,24–28
. Nevertheless, more than trying to prevent cancer by improving IBD 
treatment and surveillance, it is important to better understand the genetic and 
molecular profiles behind these cases’ carcinogenesis, not only for development of 
effective early diagnosis, prevention and treatment strategies, but also for 
identifying prognostic biomarkers.  
So far, it is known that CAC develops from an inflammatory non-dysplastic 
mucosa, which evolves into dysplasia, to invasive adenocarcinoma and the 
carcinogenic events differ from the typical adenoma-carcinoma sequence of 
sporadic CRC
29–32
. Genomic alterations detected in sporadic CRC were also 
recognized in CAC, like Wnt/β-Catenin pathway activation, p53 mutations and MYC 
amplification, but they differ significantly in frequency and in order on the 
sequence of carcinogenic events
33–38
. Moreover, considering that chronic 
inflammation secondary to chronic infection may lead to carcinogenesis, like what 
happens between Helicobacter pylori infection and gastric cancer
39–41
, in IBD, the 
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intestinal microbiome may also contribute to carcinogenesis through its interaction 
with the host damaged mucosa, metabolism and immunity
3,4
. Nevertheless, the 
immune and inflammatory response in IBD has definitely a key role in dysplasia 
and cancer development, since, prolonged over time, it leads to DNA damage
42
.  
Regarding prognostic biomarkers, few molecules are possible candidates, but 
none has cost-effectiveness evidence supporting its active search in all patients. 
Glycans have been reported to change significantly in many diseases
43–45
 including 
IBD
46,47
 and cancer
48
, so, it is likely that Glycomedicine research will yield future 
translational opportunities, including predict therapeutic response and find new 
immunomodulatory strategies for IBD treatment and CAC chemoprophylaxis. 
 
Objectives 
This scientific review aims to gadder the latest knowledge about the association 
between colorectal cancer and inflammatory bowel disease, highlighting the 
histological and molecular changes that differentiate these cases carcinogenesis 
from that of sporadic cancer, as well as the new diagnostic and prognostic 
biomarkers, underlining the importance that glycans and Glycomedicine have been 
gaining in this matter.  
This work is framed in a review article prepared by the IPATIMUP/i3S research 
group on Immunology, Cancer and Glycomedicine, of which I am coauthor, and 
whose purpose is to serve as the scientific basis for an investigation intended to 
better understand the carcinogenesis related to inflammatory bowel disease and to 
identify biomarkers in each stage of evolution from inflammation, through various 
degrees of dysplasia, to carcinoma.  
 
Methods 
Review of scientific publications accessed, mainly, through the computerized 
PubMed database, using the keywords (MeSH terms of Index Medicus) ‘Biomarkers’, 
‘Carcinogenesis’, ‘Colitis-Associated Cancer’, ‘Colorectal Cancer’, ‘Glycans’ e 
‘Inflammatory Bowel Disease’. Among the original and review articles published 
between 2008 and 2019, in English, I selected those considered of greater 
relevance and scientific rigor. Those articles references were also analyzed to 
possibly identify other publications to be included in the review.  
 
3 
COLITIS–ASSOCIATED COLORECTAL CANCER 
 
Epidemiology and Risk factors 
IBD – including CD and UC – constitutes a worldwide public health challenge, 
associated with high morbidity, mortality and health-care costs
5,6
. During the 20th 
century, IBD was mainly a western disease, with incidence rising in USA, Canada, 
western Europe, Australia and New Zealand. However, in the 21st century, an 
epidemiological shift occurred: studies from 1990 to 2016 show that IBD incidence 
plateaued or decreased in the western world, and it is rapidly rising in the newly 
industrialized countries of Asia, Africa, eastern Europe and South America
5,49–53
. This 
alteration might be due to a diminished exposure to some risk factors in western 
countries, that, oppositely, are increasing in the new industrialized society. 
Therefore, it is urgent to decipher which are the risk factors that could explain 
those geographical alterations
54
. 
The onset of IBD can occur in any age, but both CD and UC are most often 
diagnosed in late adolescence and early adulthood, between 15 and 35 years of 
age, with no gender predominance
13,53,55,56
. In Europe, the estimated incidence of CD 
and UC range from 0.5 to 10.6 cases and 0.9 to 24.3 cases per 100,000 person-
years, respectively. Despite the lowering trend in IBD incidence, the global disease 
burden remains high, which could be expectable considering the early age of onset 
and lower mortality due to improved treatment over the years. The estimated 
prevalence of IBD in Europe is around 0,3% – about 2.7 million people –, with 1.52–
213 cases of CD and 2.42–294 cases of UC per 100,000 persons. This translates 
into a direct annual healthcare cost of 4.6–5.6 billion euros. As in incidence, there 
also appears to be a north-west gradient in the prevalence of IBD
6,53
. In Portugal, as 
well as in Europe, there are approximately 150 cases of IBD per 100,000 
inhabitants, equally distributed by CD and UC, with a perception of increasing 
incidence; CD is more prevalent between 15 and 39 years of age, while UC highest 
prevalence ranges from 40 to 64 years of age; in both IBD entities, females are 
more affected
57
. 
CRC is one of the most feared complications of IBD. Although CAC accounts for 
a small percentage of all CRCs, it has worse prognosis, with 19% to 55% estimated 
5–year survival rates, being responsible for 10–15% of annual deaths of IBD 
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patients
7–10
. This high mortality is partially due to diagnosis at later stages – around 
50% of CAC patients have nodal or distant metastases at presentation
7
 – and also 
because mean age at onset of CRC in patients with IBD (estimated to be 43.2 
years
58
) is about 14 years earlier than onset of sporadic cases
10,13,38,59
. 
In general, patients with IBD have higher risk of CRC than healthy individuals, but 
this ratio varies accordingly to each patient’s characteristics. Epidemiologic studies 
are not fully consensual regarding the risk to develop CAC: most of them refer 
higher risk in UC than in CD cases, while some consider similar risk, especially 
when comparing CD involving the colon (as opposed to pure ileitis) to UC; others 
suggest a declining incidence of CRC in IBD patients over the last decade, while 
some found it stabilized. This can be attributed to differences in environmental 
factors, lifestyle and genetic susceptibility, or simply to studies design, insufficient 
study size, differences in diagnostic criteria or access to diagnostic procedures – 
countries with the latest endoscopic imaging technology may have earlier detection 
of dysplastic lesions and CAC – and different treatment guidelines, including 
criteria for performing colectomy. Comparing the meta-analyses/cohort studies by 
Eaden et al. (2001)
58
, Rutter et al. (2006)
60
 and Jess et al. (2012)
61
, it seems that 
cumulative incidence of CRC according to UC duration has been diminishing in 
recent years. Jess et al. surprisingly did not find an increased incidence of CRC in 
UC cases compared to healthy controls, which may be attributable to the higher 
rates of colostomies in UC patients in Denmark
62
. Therefore, this apparent 
decreased incidence of CAC in developed countries over the years can be related 
to improved medical and surgical treatments. 
Although the pathogenesis of CAC remains unclear, some risk factors have been 
identified: family history of CRC – increases risk of CRC as in individuals without 
IBD; inflammatory activity – persistently active IBD is associated with higher risk 
than predominantly quiescent cases; extent of affected mucosa – after 40 years of 
disease, risk of CRC is 10-15 fold increased in patients with pancolitis, and only 2 
fold increased in patients with left sided colitis (ulcerative proctitis, where 
inflammation is most severe, seems to be the exception, in which CRC risk appears 
not to be significantly  increased)
13,14
; presence of inflammatory complications – like 
perianal abscess, anal fissure, colonic strictures or inflammatory pseudopolyps; 
and concomitant primarily sclerosing cholangitis (PSC)
15–19
 – these patients have 
increased risk of CRC, compared to those with IBD alone, even after liver transplant 
(the mechanism behind this is unclear)
11,14
. Young age at diagnosis of IBD (<15 
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years) and longer disease duration are also reported as risk factors for CAC – 
estimated risk at 10, 20, and >20 years of disease is 1-3%, 2-8%, and 5-18%, with 
comparable risk associated with UC and CD
58,63
. However, as a life-long illness, IBD 
course presents periods of relapse and remission, as well as variable therapy 
response, which can influence the inflammatory damage, that may differ between 
individuals with the same disease duration. A large single-centre study from 2017 
showed that inflammatory burden in UC, estimated from a mean severity score 
calculated from all colonoscopies performed in preceding 5 years, was significantly 
associated with CAC risk, while the most recent colonoscopy evaluation alone was 
not
11
. Importantly, it seems that the cumulative inflammatory activity, more than 
disease duration, is a determining risk factor for CAC development. In fact, there 
are evidences suggesting that CAC incidence decreases when there are efficient 
surveillance strategies and successful anti-inflammatory treatment (e.g. 
aminosalicylates [5-ASA]), promoting high mucosal healing rates
12
. 
Larger and well-designed studies are needed to quantify the real burden of the 
disease. Nevertheless, more than trying to prevent CAC by improving treatment 
and follow-up of patients with IBD, it is still important to better understand the 
genetic and molecular profiles behind dysplasia and cancer development, in order 
to identify individuals at higher risk, providing earlier chemoprevention and 
therapy. 
 
CAC Vs. sporadic CRC: two distinct entities  
 
HISTOLOGY  
CAC’s mechanisms of carcinogenesis remain unknown, but it is recognized that 
it develops from an inflammatory non-dysplastic mucosa, which evolves into 
dysplasia, to invasive adenocarcinoma, diverging from the typical adenoma-
carcinoma sequence of sporadic CRC. IBD dysplastic lesions are usually multiple 
and flat, and, unlike sporadic CRC exophytic lesions, are difficult to resect 
endoscopically, often requiring colectomy because the total extent of the 
precancerous area is difficult to determine
29–32
.  
High-grade dysplastic (HGD) lesions are strongly related to CAC development and 
an indication for colectomy
64,65
, however, this approach is questionable in case of 
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low-grade dysplasia (LGD), because the progression rate to HGD or cancer is 
variable. Recently, it was shown that, among UC patients with LGD, the annual 
incidence of CRC is 0.8% and the risk of dysplasia progression increases if there is 
concomitant PSC and/or the lesions are multifocal, distally located or not 
macroscopically visible (flat)
66
. In addition, other study demonstrated a high 
prevalence of aneuploidy in HGD lesions (93.3%), and an association between 
aneuploidy in LGD lesions and their progression to HGD or CRC (in 40.5% cases). 
Therefore, aneuploidy may constitute a prognostic marker, allowing better 
management of patients with LGD
67
. 
Two patterns of dysplasia with different natural histories can be found in IBD 
patients: adenoma-like dysplasia – in areas not yet affected by the disease, where 
carcinogenesis may be considered sporadic – and non-adenoma-like dysplasia – 
where carcinogenesis is associated with the underlying chronic inflammation. While 
the first may be treated with polypectomy, the second usually requires colectomy, 
considering its higher risk of concurrent malignancy. Although they are not easily 
distinguished endoscopically or histologically, the well characterized genetic and 
molecular profiles of CAC can allow differentiate it from sporadic CRC, improving 
patients’ management31.  
 
INFLAMMATORY ENVIRONMENT 
The inflammatory environment of IBD has a key role in dysplasia and CRC 
development. In fact, some inflammation-associated genes (e.g. COX-2 and NOS-2) 
are overexpressed in IBD and in CAC
42
. Inflammation promotes releasing of reactive 
oxygen species (ROS) and inflammatory mediators (IL-6, IL-10, IL-17, IL-23, TNFα, 
VEGF), causing oxidative stress, increased cell turnover, anti-apoptotic activity, 
neoangiogenesis, migration and invasion of tumor cells
13
. Moreover, the immune 
and inflammatory response prolonged over time leads to DNA damage, which 
results in chromosomal instability (CIN) and microsatellite instability (MSI). This fact 
explains the increased risk of CAC with duration, extension and degree of 
inflammation, and why it can be attenuated by an effective disease control. The 
reason why CAC risk appears not to be increased in ulcerative proctitis remains 
unclear
13,14
. 
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GENOMIC ALTERATIONS 
Genomic alterations detected in sporadic CRC were also recognized in CAC
33–37
. 
DNA hypermethylation, commonly detected in sporadic CRC, is also common in 
CAC, involving frequently MLH1 (up to 46%) and p16 (up to 100%), and can be found 
early, in chronically inflamed mucosa without visible dysplasia
68,69
. However, other 
alterations differ in frequency and in order on the sequence of carcinogenic events. 
Recent studies
37,38
 found significant differences in genomic alterations in CAC 
tissues in comparison to the evidences reported about sporadic CRC in The Cancer 
Genome Atlas
70
 and  the Foundation Medicine database
71
:  
▪ In sporadic CRC, Wnt/β-Catenin pathway activation is the initiating event in 90% 
of cases, mostly due to APC and K-RAS mutations, with early APC tumor 
suppressor protein loss of function (in dysplastic tissue) and later activation of 
K-RAS protein (in adenoma), that promotes NF-kB mediated cytokine secretion, 
associated with inflammatory response, increased ROS release, 
neovascularization, cancer growth, invasion and metastization. In CAC, these 
mutations are rarer and occur later: K-RAS amplification in 40% of cases, in HGD, 
and APC mutations in 21% of cases, later in the dysplasia-carcinoma 
sequence
10,38
. 
▪ p53 mutations occur late in sporadic CRC, during transition from adenoma to 
carcinoma, and are found in about 50% of cases
70
, or up to 75% in advanced 
CRC
71
. But in CAC, p53 is the most commonly altered gene (in 63-89% of 
cases
37,38
) and mutations occur early, in 50% of chronically inflamed patients 
before mucosal dysplasia develops
10,13,33–38
. Mutant p53 loses the tumor 
suppressing function, allowing cytokine mediated DNA damage and prolonged 
TNFα-induced NF-kB activation. Actually, in mice harboring a germline p53 
mutation, there is severe tissue damage and HGD, rapidly progressing to 
invasive carcinoma
72
. 
▪ The most common copy number alteration in CAC is MYC amplification (in up 
to 26% of cases) – its constitutively upregulation leads to increased expression 
of many genes, some of which are involved in cell proliferation, contributing to 
the formation of cancer –, while in sporadic CRC it is rare (4%)38,70,71. 
▪ Several CAC cases have alterations in the Notch gene family (34%)38, which 
proteins are transmembrane receptors implicated in a signaling pathway which 
regulates cell-to-cell interactions that influence many cell fate decisions in 
various cell types, important during fetal development of almost all organs and 
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tissues
73
. There is no evidence in the literature of an association between notch 
mutations and CRC yet. However, other diseases and developmental changes 
are described to be associated with these mutations, such as Adams-Oliver, 
Alagille and Hajdu-Cheney syndromes, neurodegeneration, aortic valve disease, 
CADASIL (Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts 
and Leukoencephalopathy), head and neck squamous cell carcinoma and T-cell 
acute lymphoblastic leukemia
73,74
.  
 
INTESTINAL MICROBIOME 
Recent data reported that intestinal microbiome may support carcinogenesis 
through its interaction with the host damaged mucosa, metabolism and 
immunity
3,4
. It is already well known that chronic inflammation secondary to chronic 
infection may lead to carcinogenesis – one example is the association between 
gastric cancer and Helicobacter pylori infection
39–41
 – so, this possibility may also 
explain some of the CAC development.  
The possible influence of commensal flora or specific bacteria in CAC risk was 
first suggested when it was noticed that mice raised under germ-free conditions or 
treated with antibiotics did not develop neither IBD or CAC and that, comparing 
genetically identical mice, cancer only occurred in some animal facilities
75,76
.  
Some studies show that CAC cases’ microbiota differs from cancer-free 
controls
4,77
, but the doubt remains if this difference is cause or consequence of the 
cancer. CRC patients have more frequently gut dysbiosis, namely  increase of 
Fusobacterium nucleatum and decrease of butyrate-producing bacteria
4,78–80
. In fact, 
several studies support a potential active role of Fusobacterium, specifically F. 
nucleatum, in CRC development
81
. Other pathogens have been suggested to be 
initial triggers in cancer development in several animal models, most of them 
opportunistic: Escherichia coli, Enterococcus faecalis, Streptococcus gallolyticus 
and enterotoxigenic Bacteroides fragilis
4,82,83
. A study comparing fecal bacterial 
diversity in CRC patients and healthy volunteers concluded that CRC patients had 
more Bacteroides fragilis, in contrast to healthy individuals microbiota, enriched in 
B. vulgatus and B. uniformis
4
. It is interesting to see that different Bacteroides 
strains may influence the host homeostasis in different ways, therefore, further 
studies are warranted to ascertain the impact of specific species strains from the 
gut in CRC pathogenesis.  
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There is no conclusive study showing that elimination of these specific organisms 
of the gastrointestinal tract prevents CRC
80
. However, the possible influence of 
commensal flora in CRC risk might partially explain the rising incidence of CAC in 
the newly industrialized countries
5,49–53
, with recently adopted western alimentary 
habits, since diet is directly related to microbiota composition (for example, high-
fat and low-fiber diet is associated with greater cancer risk, because it induces 
dysbiosis)
82
. It is important to consider that diet potentially alters IBD and CAC risk. 
Moreover, if new studies achieve significant results about specific microbes that 
are protective against CRC development, probiotics or even fecal transplantation 
could be considered as preventive measures. 
 
IMMUNOMODULATION THERAPY  
The current IBD therapies are based on anti-inflammatory drugs (5-ASA – 
sulfasalazine, mesalazine), immunomodulators (corticosteroids, thiopurines – 
azathioprine, 6-mercaptopurine – and methotrexate) and biologic agents (mainly 
anti-tumor necrosis factor [anti-TNF] agents – Adalimumab, Infliximab), which 
suppress the immune system and can also contribute to reduce the risk of CAC, 
depending  on disease location and duration
22–24
. However, approximately 30% of 
patients do not respond to treatment and about 40% lose the initial response
20,21
. 
On the other hand, long term therapy with these agents is controversial, 
considering they may raise the risk of infections, including serious opportunistic 
infections, and promote carcinogenesis, due to reduced physiologic 
immunosurveillance of malignant cells
22
. The cancers considered secondary to 
chronic immunosuppression include mainly lymphomas and skin cancer, but also 
acute myeloid leukemia, myelodysplastic syndromes and urinary tract cancer
22,84
. 
The risk to develop any of these types of cancer vary according to the 
immunosuppressing drug class and to the patient’s age and gender. For example, 
thiopurines are associated with higher risk of postmononucleosis lymphoma and 
hepatosplenic T-cell lymphoma in younger males, but in older patients, they are 
more related to urinary tract cancers
85–88
. Moreover, while anti-TNF agents increase 
the risk of melanoma, thiopurines are associated with nonmelanocytic skin 
cancers
22,89,90
. In fact, the impact of some drugs in promoting this differential risk 
susceptibility to develop cancer in specific tissues is not yet explained.  
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To date, new therapies are being approved, involving new drug mechanisms, with 
the goal of effective disease control with fewer negative effects and finding 
solutions for the high percentage of non-responders. These include anti-adhesion 
agents (Natalizumab, Vedolizumab, Ertolizumab, AJM 300 and PF-005476659), 
anti-interleukin inhibitors (Ustekinumab and Risankizumab), janus kinase (JAK) 
inhibitors (Tofacitinib and Filgotinib) and sphingosine 1 phosphate (S1P) receptor 
modulator (Ozanimod). Their main advantages include no increased risk of 
malignancy (except with Tofacitinib) and of serious infections (with Ertolizumab, 
AJM 300, PF-005476659, Risankizumab and Ozanimod), and a less invasive 
administration, such as the oral administration of JAK inhibitors
1
. 
Recently, it was described that a gene (SERPINE-1/PAI-1) linked to blood clotting 
is highly expressed at sites of intestinal inflammation and it is specific for IBD 
patients with active disease non-responders to biologics
91
. In addition, a new 
compound (MDI-2268) was developed to suppress that gene, which resulted in 
decrease of IBD symptoms in mice. Thus, this compound  might be another new 
IBD treatment alternative with less undesirable risks
91
.  
In conclusion, to properly manage each IBD patient, it is important to assess the 
benefit/risk ratio of long-term use of immunomodulators and biologic agents, 
considering patients’ age, gender and disease phenotype. On the other hand, 
besides new drugs’ advantages and how promising they seem, it is important to 
consider that few have been available for some years (like Natalizumab), and others 
are new or still in development, so, their long-term efficacy and safety are not well 
known yet
1
. 
 
CLINICAL MANAGEMENT: THE UNMET NEEDS 
 
Prevention Strategies 
Prevention consists of a series of measures taken to avoid disease or its burden, 
defined according to successive stages of primary, secondary and tertiary 
prevention
92
. 
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PRIMARY PREVENTION – CHEMOPREVENTION 
The most striking preventive measure is primary prevention, which aims to avoid 
the onset of diseases. Translating to CAC, considering the increasing evidence that 
chronic inflammation favor’s the development of cancer in IBD, improved mucosal 
healing with 5-ASA, immunomodulators or biologics may prevent it
93
.  
Most evidence comes from observational studies of chemoprevention in UC using 
5-ASA, which effects may go beyond inflammation control
94
. 5-ASA, including 
sulfasalazine and mesalazine, are the most commonly prescribed anti-
inflammatory drugs in IBD and, despite some conflicting evidence, data suggests 
that they may confer protection against the development of colonic neoplasia
93
, as 
recently shown in a systematic review with meta-analysis
95
.  
Thiopurines (azathioprine and 6-mercaptopurine) – immunomodulators which 
inhibit purine synthesis – have demonstrated efficacy in a broad range of IBD 
complications. Once again, there is conflicting data regarding the 
chemoprophylactic effect of these drugs on dysplasia and CAC development, but 
the most recent studies suggest a trend toward a protective effect
24,96,97
. 
The evidence on the chemoprevention role of anti-TNF (infliximab and 
adalimumab) is even more scarce. Although animal models suggested that these 
biologic agents may prevent the development or progression of dysplasia and 
cancer
98
, only a few population-based studies within IBD have shown a lower 
frequency of colorectal cancer among those treated with infliximab
99,100
. 
 
SECONDARY PREVENTION – CANCER SCREENING AND SURVEILLANCE 
Assuming a key role as well, secondary prevention seeks to identify and treat 
diseases in the earliest stages before the onset of signs and symptoms. CRC 
screening programs have shown to reduce its incidence and related mortality
101
. In 
IBD patients, surveillance colonoscopy also achieved positive outcomes regarding 
CAC prevention
24,26,27
.  
Considering that IBD patients present higher risk of developing CRC, even though 
the reported risk estimates vary widely between studies, colonic surveillance is 
highly recommended
9
, in order to detect potentially resectable dysplastic lesions 
or potentially surgically curable early stage CRC, reducing its morbidity and 
mortality
9,24–28
. However, mortality reduction due to periodic follow-up has not been 
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clearly established
102–105
, which means that better techniques and surveillance 
programs are needed. Doubts remain regarding the best endoscopic technique and 
the right timing in which surveillance colonoscopies should be performed. 
The usual IBD surveillance method has been, for more than thirty years, standard 
definition (SD) colonoscopy with targeted and random biopsies every 10cm 
throughout the colon
25,31,66
. However, this technique inspects less than 5% of all the 
mucosal surface
106
 and a large retrospective analysis reviewing 1010 colonoscopies 
during ten years of surveillance quantified a small rate of dysplasia detection 
(0.19)
107
. With high definition (HD) endoscopes and monitors, dysplasia detection 
increased three-fold
28,108, which changed these patients’ management, favoring 
more conservative approaches regarding colectomy
108
.  
On the other hand, using the traditional white light endoscopy (WLE), dysplastic 
lesions may be macroscopically visible (adenoma-like) or invisible (non-adenoma-
like/flat lesions)
31,109
, but some of those invisible lesions, which have higher risk of 
concurrent malignancy
31,110,111
, are identified in dye-spray chromoendoscopy 
(DCE)
25,31,66
. In fact, the diagnostic reliability of WLE is defied in a recent review, 
which found a sensitivity of only 76% for this technique
112
, while another study 
revealed that DCE increases dysplasia detection sensitivity
113–117
, showing a 
detection rate of 9.3% with WLE, and of 21.3% with both WLE and DCE
118
. Taking 
into consideration the DCE success and its operational barriers, this technique was 
sought to be mimicked without the use of dye. Thus, virtual chromoendoscopy 
appears, facilitating the visualization of tissue abnormalities by filtration of some 
wavelengths of light – narrow-band imaging (NBI). However, compared to 
conventional WLE and DCE, the advantages of NBI are controversial
119–121
.  
To date, the most recent SCENIC (Surveillance for Colorectal Endoscopic Neoplasia 
detection and management in IBD patients: International Consensus
122
 – endorsed 
by American Gastroenterological Association [AGA] and other societies in North 
America, Europe and Asia) recommendations advocate the use of HD – rather than 
SD – colonoscopy, and DCE – rather than WLE or NBI –, with targeted biopsies of all 
identified lesions only
28,64,110,111,122,123
, as chromoendoscopy allows more targeted 
biopsies and diminishes the necessity for random ones
122
. Therefore, if there are 
no limitations of the diagnostic efficiency (poor preparation, presence of post-
inflammatory polyps or active mucosal inflammation), random biopsies on 
macroscopically normal lumen are not recommended
111,124
. Alternatively, when 
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resources and expertise for performing chromoendoscopy are not available, HD 
WLE with random biopsies is accepted
110,122,123
. 
Even though most of the evidence favor’s DCE as the gold standard technique for 
IBD patients’ surveillance, this may change in the future, since there is recent 
conflicting data. Two studies from the past 2 years presented similar dysplasia 
detection rates and shorter withdrawal times for HD colonoscopy and NBI, when 
compared to DCE
125,126
. Future studies are needed to answer the remaining 
questions concerning practical aspects, like the cost-effectiveness of the different 
procedures and the real and long-term impact of modern techniques utilization to 
increase dysplasia detection on overall CAC mortality. 
Regarding the timing of screening,  the different programs are similar. When 
comparing the most recent guidelines from AGA
110
 and form European Crohn's and 
Colitis Organization (ECCO)
123
, both recommend commence surveillance 8 years 
after onset of symptoms (not the official IBD diagnose moment), with the exception 
that, according to AGA, patients with concomitant PSC should undergo annual 
surveillance starting from the time of diagnosis. AGA recommends 1-2 years 
interval between colonoscopies and, after 2 negative exams, it can be extended to 
1-3 years, while ECCO recommendations regarding surveillance intervals range 
from 1-5 years, depending on the individual risk stratification: once a year for high 
risk patients, every 2-3 years for intermediate risk and every 5 years for low risk 
patients
110,123
. 
Alarmingly, a 16 years’ study, including seven university medical centers in The 
Netherlands, demonstrated that a substantial part of all CACs occur before colonic 
surveillance should start according to these guidelines
2
. They found out that CAC 
could appear between 0 to 45 years since IBD diagnosis and that 17% of patients 
developed cancer before the first surveillance
2
. In conclusion, strict adherence to 
these guidelines will lead to late detection of some early cancers, which may reduce 
the efficacy of colonic surveillance in IBD and explain why there is no mortality 
reduction associated with it. It is necessary to rethink if initial screening 
colonoscopy should be recommended before 8 years of disease duration for all IBD 
patients, to reassess disease extent, as colitis may progress over time. 
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Prognostic Biomarkers 
Greater knowledge about the pathogenesis of CAC at the molecular level is 
needed not only for development of effective early diagnosis, prevention and 
treatment strategies, but also for predicting therapy response and identifying 
prognostic biomarkers. So far, there are very few molecules proposed to be 
possible prognostic biomarkers and none has cost-effectiveness evidence 
supporting its active search in all IBD patients. 
As previously mentioned, the percentage of IBD patients that do not respond to 
treatment or lose the initial response is high
20,21
. Regarding CRC, there is also a 
significative resistance to chemotherapeutic drugs
127,128
 which is one of the major 
reasons for the increased mortality. A very recent study
128
 showed that cancer "stem 
cells" (CSCs) – a subset of cancer cells linked to chemoresistance129,130 – that express 
CD44v6 – a CD44 (cell-surface glycoprotein involved in cell-to-cell interaction, 
adhesion, and migration
131
) variant – are associated with more aggressive CRC 
phenotype, with higher cellular self-renewal capacity and metastatic potential
132,133
, 
increased resistance to chemotherapeutic agents and, therefore, lower disease-free 
survival (DFS) and overall survival (OS). In fact, inhibition of CD44v6 resulted in 
resensitization to chemotherapy and diminished self-renewal capacity of CSCs. In 
those CD44v6+ cells, a distinct panel of miRNAs with dysregulated profiles was 
noted, with miR-1246 upregulation being particularly related to the enhanced 
tumorigenicity. This suggests that specific miRNAs, like miR-1246, may represent 
potential prognostic biomarkers and therapeutic candidates to target CSCs
134,135
. 
Furthermore, a recent meta-analysis reported that, without any adjustment for 
molecular subtypes, the overall 5-year survival of CAC does not differ from sporadic 
CRC
136
. Another recent study
137
 demonstrated that different cancer mutational 
patterns have an impact on survival outcomes. It showed that proximally located 
CRC is related to higher mutational rates, associated with mismatch repair pathway 
defects (dMMR), mostly due to MLH1 protein loss of expression. Patients with these 
types of cancer had a significantly better survival rate, compared with non-
hypermutated ones. Moreover, this study found that the increased survival of 
sporadic CRC cases with MSI
138
 has also been observed in CAC. The neo-epitopes 
generated by the high mutational rate cause an anti-tumor infiltrating lymphocytes 
response that is thought to have an important role in the improved survival of these 
dMMR/MSI cancers
137
. 
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Additionally, it would be interesting to consider an analogous molecular profiling 
for CAC as used in gastric cancer, considering that both are inflammation-
associated
139
. Thus, future studies are required to determine whether combinatory 
analysis of p53 alterations – the most commonly altered gene in CAC37,38 – and MLH1 
loss of expression in the biopsies’ tissue taken during IBD patients colonoscopic 
surveillance could identify patients with higher risk of developing CAC
139
.  
Overall, there is an urgent need for recognizing the molecular landscape behind 
CAC. Information concerning prognostic biomarkers is scarce, and new studies are 
needed in this area, to clarify the different treatment responses and help clinicians 
give a more reliable prognostic estimate to patients. 
 
Can Glycomedicine have a role? 
Most extracellular and membrane proteins are glycosylated, and glycosylation 
alterations significantly affect the protein structure and function
141,142
. The cellular 
profile of glycans has been reported to change significantly in various diseases
43–45
 
including IBD
46,47
 and cancer
48
, so it is likely that Glycomedicine research will yield 
future translational opportunities. 
Particularly, complex branched N-glycans are known to play key roles in many 
glycoproteins in cancer
48,143–145
 and in autoimmune disorders
146,147
, through T cell 
activation (via T cell receptor [TCR] signaling) and function. Mucosal T lymphocytes 
from patients with active UC were previously shown to display a deficiency in 
branched N-glycosylation, and mice models with absence of this type of glycans 
develop early-onset and severe disease
148
. The i3s research group recently 
demonstrated in human ex vivo models that supplementation of mucosal T cells 
(isolated from patients with active UC) with N-acetylglucosamine (GlcNAc) lead to 
an enhancement of branched N-glycosylation on the TCR, which was associated 
with more controlled T cell-mediated immune response. Nonetheless, mice with 
severe colitis treated with GlcNAc revealed a clinical improvement, namely better 
clinical scores and suppression of disease progression
148
. These results repurposed 
GlcNAc as an inexpensive and nontoxic targeted-specific immunomodulatory 
strategy for IBD treatment, and eventually a potential chemoprophylaxis agent to 
primary prevention of CAC. 
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Remarkably, glycans can also be useful for IBD prognosis. Recently, the i3s 
research group showed that they can discriminate, early in the disease course, 
which patients are most likely to develop severe colitis and fail to respond to 
standard therapy, benefiting from other therapeutic strategies initially (e.g. 
biologics). This study demonstrated that low levels of branched N-glycans around 
time of diagnosis is an independent predictor of non-response to conventional 
therapy with 75% of specificity, and, correspondingly, high levels of branched N-
glycans predict 78% of UC patients that will have a favorable disease course 
exclusively under 5-ASA treatment with more than 5 years disease
149
. 
Other interesting serologic markers that can differentiate CD from UC and help 
determine the course of the disease are anti-glycan antibodies – like anti-
mannobioside carbohydrate IgG antibodies (AMCA), anti-chitobioside carbohydrate 
IgA (ACCA) and antilaminaribioside carbohydrate IgG antibodies (ALCA) –, alone or 
combined with anti-Saccharomyces cerevisiae (ASCA) and perinuclear 
antineutrophil cytoplasmic antibody (pANCA), which can be seen in a subgroup of 
patients with IBD
150–152
. High levels of these antibodies can be related with a high 
probability to develop complicated IBD, leading to increased risk of IBD-related 
surgery, as shown in a recent study, that found anti-glycan antibodies, especially 
AMCA, to be valuable biomarkers to promptly classify patients into high risk for 
severe disease
151–153
. Another recent study investigated the same antibodies – 
pANCA, ASCA, AMCA, ACCA and ALCA – in newly diagnosed, untreated IBD 
patients, concerning disease phenotype and course, and analyzed their presence 
over time. This study concluded that anti-glycans may fluctuate under the influence 
of immunosuppressive treatment, which is congruent with the hypothesis that they 
may be risk biomarkers. Also, it showed that antibody profiles at diagnosis, namely 
pANCA and ASCA, enable good discrimination between CD (ASCA+, pANCA-) and 
UC (ASCA-, pANCA+), and that pANCA status over time is associated with UC 
activity, having the potential to be used in disease monitoring
154
. A meta-
analysis/systemic review designed to evaluate the diagnostic value of anti-glycan 
biomarkers and their association with IBD complications and need for surgery, 
confirmed these results, concluding that ASCA had the highest diagnostic value for 
differentiating IBD from no disease and CD from UC, and that ACCA had the highest 
association with complications. Moreover, it showed that combination of 2 markers 
had a better diagnostic value as well as higher association with complications and 
need for surgery than any individual marker alone
155
. 
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It is also known that immunoglobulin G (IgG) Fc-glycosylation levels affects IgG 
effector functions. Interestingly, IgG in mice can have pro-and anti-inflammatory 
activity, depending on its glycosylation status
156,157
. A recent retrospective analysis 
of plasma samples from patients with IBD and healthy individuals (controls), found 
an association between IgG Fc-glycosylation levels with disease and its clinical 
features: patients with IBD had lower levels of IgG glycosylation than controls, 
namely low galactoslation, which was associated with more severe CD or UC and 
related to the need for surgery
158
. This brings to light the possibility of a minimally 
invasive biomarker for IBD, by measuring serum protein glycosylation levels. 
In conclusion, this new era of glycomics revealed a new window of opportunities 
for the management of IBD patients and consequently, prevention of CAC. The 
promising role of Glycomedicine, namely, new serological biomarkers in 
stratification of patients according to disease phenotype and risk of complications, 
can restructure the actual prevention programs by helping predict the disease 
course and therapeutic response. 
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Conclusions 
Despite the lowering trend in IBD incidence, the global disease burden remains 
high. Epidemiologic studies are not fully consensual regarding the risk to develop 
CAC, nevertheless, it is one of the most feared complications of IBD, being 
responsible for 10–15% of annual patients’ deaths7–10 and this high mortality is due 
to cancer early onset and late diagnosis
7,10,13,38,58,59
. 
The pathogenesis of CAC remains unclear, but the inflammatory burden seems 
to have a key role
11,12
. Although there is conflicting data about the 
chemoprophylactic effect of 5-ASAs and thiopurines, recent studies suggest they 
are protective
24,96,97
. The evidence about anti-TNF on cancer prevention is more 
scarce
98–100
. Alarmingly, though these therapies may reduce the risk of CAC
22–24
, 
chronically, they raise the risk of infections and promote carcinogenesis
22
, so, to 
properly manage patients, it is important to assess the benefit/risk ratio of long-
term use of these drugs. To date, new therapies are being approved to find 
solutions for the high percentage of non-responders
20,21, which is a great clinicians’ 
concern. Their main advantages include less undesired risks, in addition to less 
invasive administration
1,91
. Besides how promising these drugs seem, they are 
recent or still in development, so, their long-term efficacy and safety are not well 
known yet
1
. 
Also regarding CAC prevention, colonic surveillance is highly recommended
9
. The 
most recent guidelines advocate the use of HD DCE, with targeted biopsies of all 
identified lesions only (SCENIC)
28,64,110,111,122,123
, and commence surveillance 8 years 
after onset of symptoms, with 1-2 years (AGA) or 1-5 years interval (ECCO)
110,123
. 
However, doubts remain regarding the best technique and right timing in which 
colonoscopies should be performed, since some CACs occurred before colonic 
surveillance started
2
, which may explain why there is no mortality reduction with 
surveillance
102–105
. Future studies are needed to clarify the remaining doubts, like 
the real long-term impact of improved dysplasia detection on overall CAC mortality. 
Greater knowledge about CAC’s pathogenesis at the molecular level is needed, 
for effective early diagnosis, prevention, treatment and prognosis. Though new 
discoveries about CAC carcinogenesis have recently been made, it remains 
incompletely understood. So far, it is known that CAC develops from an 
inflammatory non-dysplastic mucosa, that evolves into dysplasia, to invasive 
adenocarcinoma, which differs from the typical adenoma-carcinoma sequence of 
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sporadic CRC. In fact, recent studies showed that HGD lesions are strongly related 
to CAC development
64,65
, and that LGD lesions have higher risk of progression if the 
patient has concomitant PSC, if there is high prevalence of aneuploidy and/or the 
lesions are multifocal, distal or flat
66,67
. Other studies found that some 
inflammation-associated genes are overexpressed in IBD and in CAC
42
 and that the 
chronic immune and inflammatory response leads to DNA damage, explaining the 
increased cancer risk with duration, extension and degree of inflammation. The 
reason why CAC risk appears not to be increased in ulcerative proctitis remains 
unclear
13,14
. The genomic alterations detected in sporadic CRC were also recognized 
in CAC
33–37
, but with significant differences, for example, in CAC Wnt/β-Catenin 
pathway activation is rarer and occurs later
10,38
 and p53 is the most commonly 
altered gene and mutations occur earlier
10,13,33–38
. Another interesting finding was 
the percentage of CAC cases with alterations in the Notch gene family (34%)
38
, since, 
though other diseases and developmental changes are associated with these 
mutations, there is no evidence in the literature of an association with CRC yet
73,74
. 
The possibility of an intestinal microbiome’ role in carcinogenesis was supported 
recently
3,4
, since CRC patients have more gut dysbiosis than healthy individuals, 
namely  increase of F. nucleatum, decrease of butyrate-producing bacteria
4,78–80, and 
more B. fragilis, in contrast to healthy individuals microbiota, enriched in B. 
vulgatus and B. uniformis
4
. Therefore, further studies are needed to establish the 
impact of specific species strains in CRC pathogenesis and discover microbes that 
may be protective against CRC development, so that probiotics or even fecal 
transplantation could be considered as potential preventive measures.   
Regarding disease biomarkers, recent studies found some candidates. Specific 
miRNAs may help in prognosis and treatment, since a distinct panel of miRNAs with 
dysregulated profiles was noted in CSCs CD44v6+, cells associated with more 
aggressive cancer phenotype and chemotherapy resistance
128,134,135
. Also, high 
dMMR/MSI mutational rates are associated with improved survival
137
. 
Glycomedicine seems very promising in this matter. Recent studies showed that 
levels of branched N-glycans
149
 and anti-glycan antibodies (AMCA, ACCA and 
ALCA)
150–153,155
 can constitute early prognostic biomarkers and that GlcNAc can be 
an inexpensive and nontoxic targeted-specific immunomodulatory strategy for IBD 
treatment and CAC chemoprophylaxis
159
. IgG Fc-glycosylation levels were also 
associated with IBD and its clinical features, since low galactoslation was associated 
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with more severe disease phenotype
158
, raising the possibility of a minimally 
invasive biomarker, by measuring serum protein glycosylation levels. 
Though information about biomarkers is scarce, this new era of glycomics opens 
a new window of opportunities, since Glycomedicine may find new serological 
biomarkers to help in patients’ stratification according to IBD phenotype and risk 
of complications, by helping predict the disease course and therapeutic response. 
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